ES2148313T3 - Diagnostico precoz de la mucoviscidosis o de una mutacion del gen cftr. - Google Patents

Diagnostico precoz de la mucoviscidosis o de una mutacion del gen cftr.

Info

Publication number
ES2148313T3
ES2148313T3 ES94902859T ES94902859T ES2148313T3 ES 2148313 T3 ES2148313 T3 ES 2148313T3 ES 94902859 T ES94902859 T ES 94902859T ES 94902859 T ES94902859 T ES 94902859T ES 2148313 T3 ES2148313 T3 ES 2148313T3
Authority
ES
Spain
Prior art keywords
pct
hpap
mucoviscidosis
mutation
early diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94902859T
Other languages
English (en)
Inventor
Juan-Lucio Iovanna
Jean-Charles Dagorn
Volker Keim
Jacques Sarles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2148313T3 publication Critical patent/ES2148313T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4733—Acute pancreatitis-associated protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/382—Cystic fibrosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRESENTE SOLICITUD SE REFIERE AUN PROCESO PARA LA DETECCION IN VITRO DE UNA AFECCION PANCREATICA ASOCIADA A UNA ALTERACION DEL GEN CFTR, CARACTERIZADO EN QUE SE DOSIFICA LA CONCENTRACION DE PAP HUMANA EN UNA MUESTRA BIOLOGICA. SE REFIERE TAMBIEN A ANTICUERPOS APROPIADOS PARA REALIZAR ESTA DOSIFICACION.
ES94902859T 1992-12-24 1993-12-23 Diagnostico precoz de la mucoviscidosis o de una mutacion del gen cftr. Expired - Lifetime ES2148313T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9215730A FR2700011B1 (fr) 1992-12-24 1992-12-24 Détection de la mucoviscidose ou d'une mutation du gêne CFTR au moyen d'un dosage de la PAP.

Publications (1)

Publication Number Publication Date
ES2148313T3 true ES2148313T3 (es) 2000-10-16

Family

ID=9437118

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94902859T Expired - Lifetime ES2148313T3 (es) 1992-12-24 1993-12-23 Diagnostico precoz de la mucoviscidosis o de una mutacion del gen cftr.

Country Status (9)

Country Link
US (1) US5834214A (es)
EP (1) EP0676052B1 (es)
JP (1) JPH08508093A (es)
AT (1) ATE191793T1 (es)
CA (1) CA2152166C (es)
DE (1) DE69328376T2 (es)
ES (1) ES2148313T3 (es)
FR (1) FR2700011B1 (es)
WO (1) WO1994015218A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815129B1 (en) * 1995-02-22 2011-01-05 Eastern Virginia Medical School of the Medical College of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
US5834590A (en) 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
US6458076B1 (en) 2000-02-01 2002-10-01 5 Star Medical Multi-lumen medical device
WO2003073103A1 (de) * 2002-02-26 2003-09-04 Hermann Schillers Verfahren zum nachweis von erkrankungen, die auf defekten des proteins cystic fibrosis transmembrane conductance regulator (cftr) beruhen
US20030212000A1 (en) * 2002-05-09 2003-11-13 Medtronic Minimed, Inc. Immunoprotective methods for beta cell neogenesis
WO2005000096A2 (en) * 2003-06-05 2005-01-06 Hydrocision, Inc. Disposable endoscope and method of making a disposable endoscope
EP1488798A1 (en) * 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
US20070224638A1 (en) * 2006-03-27 2007-09-27 Institut Pasteur Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
US20160039877A1 (en) 2013-03-15 2016-02-11 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US4322274A (en) * 1980-08-28 1982-03-30 Wilson Gregory B Method of diagnosing cystic fibrosis patients and asymptomatic carrier of the cystic fibrosis gene
WO1991002796A1 (en) * 1989-08-22 1991-03-07 Hsc Research Development Corporation Cystic fibrosis gene
CA2037478A1 (en) * 1990-03-05 1991-09-06 Richard Gregory Diagnostic and treatment methods involving the cystic fibrosis transmembrane regulator
FR2661187B1 (fr) * 1990-04-20 1994-08-05 Inst Nat Sante Rech Med Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.

Also Published As

Publication number Publication date
DE69328376D1 (de) 2000-05-18
EP0676052B1 (fr) 2000-04-12
FR2700011A1 (fr) 1994-07-01
EP0676052A1 (fr) 1995-10-11
WO1994015218A1 (fr) 1994-07-07
CA2152166C (fr) 2004-04-27
FR2700011B1 (fr) 1995-02-24
JPH08508093A (ja) 1996-08-27
DE69328376T2 (de) 2000-12-21
US5834214A (en) 1998-11-10
ATE191793T1 (de) 2000-04-15
CA2152166A1 (fr) 1994-07-07

Similar Documents

Publication Publication Date Title
Tuszynski et al. Thrombospondin promotes cell-substratum adhesion
BR0112026A (pt) Anticorpos com dupla especificidade e métodos de produção e uso
LU91237I2 (fr) Palifermin et ses dérivés pharmaceutiquement acceptables (kepivance)
AU5665696A (en) Novel methods for the assay of troponin i and t and complexe s of troponin i and t and selection of antibodies for use in immunoassays
WO1994016094A3 (en) Recombinant anti-vla4 antibody molecules
NO331148B1 (no) Anvendelse av et monoklonalt eller polyklonalt antistoff, samt fremgangsmate og kit for in vitro diagnose.
US5726061A (en) Method of diagnosing and monitoring colorectal cancer
ATE175241T1 (de) Antikörper gegen alpha v beta 3 integrin
ATE197592T1 (de) Monoklonaler antikörper gegen cd44v6
ES2148313T3 (es) Diagnostico precoz de la mucoviscidosis o de una mutacion del gen cftr.
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ATE115729T1 (de) Testverfahren und reagenziensatz dafür.
EP0350690A3 (de) Neutralisation der in vitro- und in vivo-toxischen Eigenschaften von TNF-alfa durch monoklonale Antikörper und die davon abgeleiteten Fragmente
AU7336400A (en) Diagnostic assay for type 2 heparin-induced thrombocytopenia
EP0974671A8 (en) Method for diagnosing bone dysbolism
ATE397659T1 (de) Polyklonale antikörper gegen den menschlichen alpha-pdgf-rezeptor und dessen verwendung
AU4948999A (en) Method of diagnosing cardiovascular disease and early atherosclerosis
Schratzberger et al. Interleukin-8-induced human peripheral blood B-lymphocyte chemotaxis in vitro
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
CA2065404A1 (en) Assays and reagents for amyloid deposition
AR246766A1 (es) Hibridoma apropiado para producir anticuerpos monoclonales utiles para el diagnostico de brucelosis.
CA2286335A1 (en) Methods of obtaining antigens specific for fungi, antibodies for such antigens, and diagnosis of disease using such antigens and/or antibodies
DE69229948T2 (de) hGPIIb-FRAGMENTE UND IHRE VERWENDUNG IN IN-VITRO-VERFAHREN ZUR BESTIMMUNG VON IN VIVO STATTFINDENDEN THROMBOTISCHEN EREIGNISSEN
ATE209359T1 (de) Bestimmung von freiem und komplexiertem trypsinogen-2
WO2000017658A3 (en) Diagnosis of myocardial disease or stroke using factor ix activation peptide

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 676052

Country of ref document: ES